Shares of Exact Sciences Corporation fell 4.4% In Tuesday’s post-market trading after the cancer screening and diagnostic tests provider reported lower-than-expected 4Q earnings. Meanwhile, exact Sciences (EXAS) posted a loss per share of $2.79 during the fourth quarter, which was higher than the $0.22 loss per share expected by analysts. Revenue increased about 58% year-on-year to $466.3 million topping analysts’ estimates of $446.22 million. During the quarter its screening revenue which includes revenue from Cologuard and Biomatrica products rose 9% to $249.7 million. Revenue from COVID-19 testing was $99.1 million. Exact Sciences acquired Base Genomics in 4Q and recorded the acquisition as a $412.6 million charge to R&D expense.